Navigation Links
Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Date:4/28/2008

SANTA MONICA, Calif., April 28 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that the Company is compiling data for its Phase 2 testing results of Rh-Apo2L and expects to announce the findings within the next month. The Company previously announced that the target cancers for the drug have been determined and initial results are extremely positive. The cancer targets that the Company has chosen are ailments which Rh-Apo2L has shown the most efficacy and which have the most market potential. The Company previously announced that Rh-Apo2L testing results have shown strong efficacy in treating non-small cell lung cancer, non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer.

The Company intends to immediately file for Phase 3 clinical testing with the People's Republic of China's State Food and Drug Administration after the announcement of the findings from Phase 2 testing. The Company anticipates that the Chinese government will then allow for the commencement of Phase 3 testing within two to three months after the Phase 2 results are published. Phase 3 testing will entail large-volume tests on over 300 patients and is the last step before it may be commercially sold in the People's Republic of China.

About Rh-Apo2L- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. This biopharmaceutical drug has gained the attention of researchers and clinical professionals throughout the People's Republic of China who are observing the drug for potential replacement of surgery and radiation therapy for cancer. Potentially, over 8 million lives can be saved each year in the People's Republic of China by this drug.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanc
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
2. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
5. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
6. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
7. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
9. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
10. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
11. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
(Date:9/18/2014)... Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 ... Acid Industry" and "2014 Deep Research Report on ... its research database. Photo - ... Report on Global and China Acetic Acid Industry" ... China and Global Acetic ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... are subject to a wide array of federal government ... report published by the nonprofit American Botanical Council (ABC). ... dietary supplements that are granted to the U.S. Food ... (FTC), as well as other government agencies. ...
... TRIANGLE PARK, N.C., Feb. 6, 2012  Chimerix, Inc., ... announced positive results from CMX001 Study 201, a ... of cytomegalovirus (CMV) disease in hematopoietic stem cell ... Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the ...
... Inc., a critical care company focused on developing and commercializing ... ill patients in the hospital and ICU settings, today announced ... the 14th Annual BIO CEO & Investor Conference.  Mr. Tasse,s ... 3:30 p.m. EST in the Park South of the Waldorf ...
Cached Biology Technology:Dietary Supplements Extensively Regulated, Say Authors of New Article 2Dietary Supplements Extensively Regulated, Say Authors of New Article 3Dietary Supplements Extensively Regulated, Say Authors of New Article 4Dietary Supplements Extensively Regulated, Say Authors of New Article 5Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 2Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 3Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 4Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 5Ikaria® to Present at 14th Annual BIO CEO & Investor Conference 2
(Date:9/18/2014)... The ability to acquire and creatively manipulate spoken language ... over the past 6 million years of human evolution ... is the best candidate gene we now have," says ... LMU. In his efforts to understand the molecular biological ... step forward. The results of his latest study, undertaken ...
(Date:9/18/2014)... cheerful, happy-go-lucky characters, so you might expect that most ... In fact some dogs are distinctly more pessimistic than ... , "This research is exciting because it measures positive ... It offers researchers and dog owners an insight into ... Dr Melissa Starling, from the Faculty of Veterinary Science. ...
(Date:9/18/2014)... is it that when people are too stressed they ... from the Brain Mind Institute (BMI) at EPFL have ... relationship between chronic stress and the loss of social ... enzyme attacks a synaptic regulatory molecule in the brain. ... Nature Communications . , Carmen Sandi,s team went ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3How stress tears us apart 2
... new species of dinosaur unearthed in Mexico is giving scientists ... according to an international research team led by scientists from ... Utah. To date, the dinosaur record from Mexico has ... Museum of Natural History, Utahs designated natural history museum. ...
... U.S. Department of Homeland,Security (DHS) announced today ... international visitors arriving at San Francisco,International Airport ... the,department,s upgrade from two- to 10-fingerprint collection ... more accurately and,efficiently establishing and verifying visitors, ...
... at the Moores Cancer Center at University of California, San ... who were treated with a gene therapy protocol began making ... will be published on line the week of February 11-15 ... Academy of Science. Researchers led by Thomas J. Kipps, ...
Cached Biology News:New dinosaur from Mexico offers insights into ancient life on West America 2New dinosaur from Mexico offers insights into ancient life on West America 3New dinosaur from Mexico offers insights into ancient life on West America 4New dinosaur from Mexico offers insights into ancient life on West America 5New dinosaur from Mexico offers insights into ancient life on West America 6DHS Begins Collecting 10 Fingerprints From International Visitors at San Francisco International Airport 2Gene therapy protocol at UCSD activates immune system in patients with leukemia 2
... of a class of proteins who function to ... S plays an integral role in proofreading the ... excision repair and in preventing chromosomal recombination between ... DNA specifically at base pair mismatches and small ...
TGase3 (S-20)...
... the industrys first PCI Express image acquisition ... acquire images at the highest speeds, resolutions, ... cameras to perform demanding imaging applications such ... analysis, and advanced motion tracking. In ...
Simple operation and an easy-to-read LCD display characterize our Classic Light balances. * Taring range 0...1510 g...
Biology Products: